论文部分内容阅读
目的分析比较埃索美拉唑与奥美拉唑治疗反流性食管炎(RE)的临床疗效。方法 116例反流性食管炎患者,随机分为研究组和对照组,每组58例。在莫沙必利治疗基础上,研究组采用埃索美拉唑治疗,对照组采用奥美拉唑治疗。比较两组的临床疗效、症状评分及不良反应发生情况。结果研究组总有效率93.10%高于对照组的75.86%,差异具有统计学意义(P<0.05)。治疗前两组患者症状评分比较差异无统计学意义(P>0.05),治疗后8周研究组症状评分(0.21±0.04)分明显低于对照组的(0.93±0.08)分,差异具有统计学意义(P<0.05)。治疗过程中,对照组不良反应发生率6.90%与研究组的5.17%比较差异无统计学意义(P>0.05)。患者不良反应症状轻微,停药后均自行缓解,未影响疗程。结论对于反流性食管炎采用埃索美拉唑治疗疗效更确切,不良反应少,值得推广应用。
Objective To compare and analyze the clinical efficacy of esomeprazole and omeprazole in the treatment of reflux esophagitis (RE). Methods 116 patients with reflux esophagitis were randomly divided into study group and control group, 58 cases in each group. On the basis of mosapride treatment, the study group treated with esomeprazole and the control group treated with omeprazole. The clinical efficacy, symptom scores and adverse reactions were compared between the two groups. Results The total effective rate in the study group was 93.10%, which was significantly higher than that in the control group (75.86%, P <0.05). There was no significant difference in symptom scores between the two groups before treatment (P> 0.05). After 8 weeks of treatment, the symptom score of the study group (0.21 ± 0.04) was significantly lower than that of the control group (0.93 ± 0.08), the difference was statistically significant Significance (P <0.05). In the course of treatment, the incidence of adverse reactions in the control group was 6.90%, which was not significantly different from that of the study group (5.17%) (P> 0.05). Minor adverse reactions in patients with symptoms, self-remission after stopping, did not affect the course of treatment. Conclusion The esophageal cure for reflux esophagitis is more effective and less adverse reactions, so it is worth popularizing and applying.